

Solid-Phase Synthesis and Bioevaluation of Lupeol-Based Libraries as Antimalarial Agents


Bioorg. Med. Chem. Lett. 12 (2002) 2803

T. Srinivasan,^a G. K. Srivastava,^a A. Pathak,^a S. Batra,^a K. Raj,^a Kshipra Singh,^b S. K. Puri^b and B. Kundu^{a,*}

^aMedicinal Chemistry Division, Central Drug Research Institute, Lucknow-226 001, India

^bParasitology Division, Central Drug Research Institute, Lucknow-226 001, India

The use of the triterpenoid lupeol as a scaffold for the synthesis of lupeol-based libraries is described. Lupeol was anchored to a solid support (Rink amide/Siebert Amide) through aliphatic dicarboxylic acid moieties, which also served as a site for introducing diversity. The resulting polymer linked 3 β -O (resin-alkanoyl)-lup-20(29)-ene **3** was used to generate key intermediates 3 β -O (resin-alkanoyl)-30-bromo-lup-20(29)-ene **4** and 3 β -O (resin-alkanoyl)-30-amino-lup-20(29)-ene **6** for the generation of libraries based on disubstituted lupeol derivatives. A 96-member library was screened for its in-vitro antimalarial activity against *Plasmodium falciparum*.



New Rev-Transport Inhibitor with Anti-HIV Activity from Valerianae Radix

Bioorg. Med. Chem. Lett. 12 (2002) 2807


Nobutoshi Murakami,^a Ying Ye,^a Motoyuki Kawanishi,^a Shunji Aoki,^a Nobuaki Kudo,^b Minoru Yoshida,^b Emi E. Nakayama,^c Tatsuo Shioda^c and Motomasa Kobayashi^{a,*}

^aGraduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan

^bGraduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan

^cResearch Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan

Bioassay-guided separation by use of the fission yeast expressing the NES of Rev resulted in isolation of valtrate (**1**) as a new Rev-transport inhibitor from Valerianae Radix.




Convenient Synthesis and Evaluation of Enzyme Inhibitory Activity of Several N-Alkyl-, N-Phenylalkyl, and Cyclic Isoorea Derivatives of 5a-Carba- α -DL-fucopyranosylamine

Bioorg. Med. Chem. Lett. 12 (2002) 2811

Seiichiro Ogawa,^{*} Makiko Mori, Goichi Takeuchi, Fuminao Doi, Maiko Watanabe and Yuko Sakata

Department of Life Sciences and Informatics, Faculty of Science and Technology, Keio University, Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan




New Highly Active Taxoids from 9 β -Dihydrobaccatin-9,10-acetals. Part 2

Bioorg. Med. Chem. Lett. 12 (2002) 2815

Takashi Ishiyama, Shin Iimura, Toshiharu Yoshino, Jun Chiba, Kouichi Uoto, Hirofumi Terasawa and Tsunehiko Soga^{*}

Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo R&D Center, 16-13 Kita-kasai 1-Chome Edogawa-ku, Tokyo 134-8630, Japan

The dramatic improvement of the activity of 9 β -dihydro taxoids by modification of the 7 and/or 3' positions is reported.




The First Synthesis and Antifungal Activities of 9-Methoxystrobilurin-type β -Substituted β -Methoxyacrylate

Bioorg. Med. Chem. Lett. 12 (2002) 2821

Hiromi Uchiro, Koh Nagasawa, Tomoya Kotake, Daiju Hasegawa, Aya Tomita and Susumu Kobayashi*

Faculty of Pharmaceutical Sciences, Tokyo University of Science, 12 Ichigayafunagawara-machi, Shinjuku-ku, Tokyo 162-0826, Japan

The first synthesis of 9-methoxystrobilurin-type β -substituted MOAs was successfully achieved. Antifungal activities of the synthesized compounds against several representative fungi were examined and superior antifungal properties of 9-methoxystrobilurin-type β -substituted MOAs compared with those of oudemansin-type analogue were clearly revealed.



Ar = Ph, α -Naphthyl, β -Naphthyl, Thienyl etc.

Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors

Bioorg. Med. Chem. Lett. 12 (2002) 2825


Kristel Senten,^a Pieter Van der Veken,^a Gunther Bal,^a Ingrid De Meester,^b Anne-Marie Lambeir,^b Simon Scharpé,^b Brigitte Bauvois,^c Achiel Haemers^a and Koen Augustyns^{a,*}

^aDepartment of Medicinal Chemistry, University of Antwerp (UIA), Universiteitsplein 1, B-2610 Antwerpen, Belgium

^bDepartment of Medical Biochemistry, University of Antwerp (UIA), Universiteitsplein 1, B-2610 Antwerpen, Belgium

^cInstitut Curie, Pavillon Pasteur, Unité INSERM 365, 26, rue d'ULM, 75231 Paris Cedex 05, France

The design and synthesis of a series of DPP II inhibitors are reported, in which the most potent and selective Dab-Pip has an IC₅₀ = 0.13 μ M and a 7600-fold selectivity with respect to DPP IV.



24


Synthesis and Kinase Inhibitory Activity of 3'-(S)-*epi*-K-252a

Bioorg. Med. Chem. Lett. 12 (2002) 2829

Diane E. Gingrich and Robert L. Hudkins

Department of Medicinal Chemistry, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA

The 3'-*epi* diastereomer of K-252a (**2**) was synthesized resulting in a 19 nM inhibitor of VEGFR2 and a 1 nM inhibitor of TrkA tyrosine kinase.



epi-2


A Multidetachable Sulfamate Linker Successfully Used in a Solid-Phase Strategy to Generate Libraries of Sulfamate and Phenol Derivatives

Bioorg. Med. Chem. Lett. 12 (2002) 2833

Donald Poirier,* Liviu C. Ciobanu and Marie Bérubé

Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center and Laval University, Centre Hospitalier Universitaire de Québec (CHUQ), Pavillon CHUL, 2705 Laurier Boulevard, Québec, Qc, Canada G1V 4G2

Four model libraries of enzyme inhibitors were rapidly synthesized in very good yields and purities.



R' = SO₂NH₂ (A)
or R' = H (B)

Benzodiazepine Inhibitors of the MMPs and TACE


Bioorg. Med. Chem. Lett. 12 (2002) 2867

Frances C. Nelson,^{a,*} Efren Delos Santos,^a Jeremy I. Levin,^a James M. Chen,^a Jerauld S. Skotnicki,^a John F. DiJoseph,^b Michele A. Sharr,^b Amy Sung,^b Loran M. Killar,^b Rebecca Cowling,^a Guixian Jin,^a Catherine E. Roth^b and J. Donald Albright^a

^aWyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA

^bWyeth Research, PO Box CN8000, Princeton, NJ 08543, USA

A series of benzodiazepine inhibitors of the MMPs and TACE has been developed. These compounds display an interesting selectivity profile and should be useful tools for exploring the biological relevance of such selectivity.




Synthesis of Poly(maleimide-co-2-ethylacrylic Acid) and Its Properties of Suppressing Metastasis and Growth of Carcinoma

Bioorg. Med. Chem. Lett. 12 (2002) 2843

Zhongliang Zhu, Lianjun Shi and Junlian Huang

Department of Macromolecular Science, The Key Laboratory of Molecular Engineering, Education Ministry of China, Fudan University, Shanghai 200433, People's Republic of China

A series of copolymers with different contents and composition is prepared using maleimide and 2-ethylacrylic acid as comonomer. This kind of copolymer shows low toxicity (LD₅₀: 601–798 mg/kg) and significant curative effect on Lewis lung carcinoma and S180.




Synthesis of Nitrile Derivatives of Estrogens

Bioorg. Med. Chem. Lett. 12 (2002) 2847

Hasrat Ali and Johan E. van Lier*

CIHR Group in the Radiation Sciences, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada J1H 5N4

The nature of the 11β-substituent strongly affects the conversion of 19-nortestosterone to estrogen derivatives.



Antitumor Agents. Part 215: Antitubulin Effects of Cytotoxic B-Ring Modified Alcolchicinoids

Bioorg. Med. Chem. Lett. 12 (2002) 2851


Shiqing Han,^a Ernest Hamel,^b Kenneth F. Bastow,^a Andrew T. McPhail,^c Arnold Brossi^a and Kuo-Hsiung Lee^{a,*}

^aNatural Products Laboratory, School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA

^bScreening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA

^cDepartment of Chemistry, Paul M. Gross Chemical Laboratory, Duke University, Durham, NC 27708, USA

N-Acetylcolchicol methyl ether **1** served as the starting material to prepare the chloroacetamide (**3**) and epoxide (**5**) analogues. Both **3** and **5** were potent inhibitors of tubulin polymerization in vitro.



Combinatorial Library of Indinavir Analogues: Replacement for the Aminoindanol at P₂'


Bioorg. Med. Chem. Lett. 12 (2002) 2855

Subharekha Raghavan,^{a,*} Zheng Yang,^a Ralph T. Mosley,^a William A. Schleif,^b Lori Gabryelski,^b David B. Olsen,^b Mark Stahlhut,^b Lawrence C. Kuo,^b Emilio A. Emini,^b Kevin T. Chapman^a and James R. Tata^a

^aDepartment of Medicinal Chemistry Merck Research Laboratories, Rahway, NJ 07065, USA

^bDepartment of Antiviral Research Merck Research Laboratories, West Point, PA 19486, USA

A combinatorial library of indinavir analogues was synthesized on the solid support to identify a replacement for the aminoindanol moiety at P₂'. 2,6-Dimethyl-4-hydroxy phenol was discovered to be a good replacement for aminoindanol.



Design, Synthesis and Evaluation of 4-Imidazolylflavans as New Leads for Aromatase Inhibition

Bioorg. Med. Chem. Lett. 12 (2002) 2859

Christelle Pouget, Catherine Fagnere, Jean-Philippe Basly, Gérard Habrioux and Albert José Chulia*

UPRES EA 1085, 'Biomolécules et cibles cellulaires tumorales', Faculté de Pharmacie, 2 rue du Docteur Marcland, 87025 Limoges cedex, France

Two 4-imidazolylflavans were synthesized and their stereochemistry was established by ¹H and ¹³C NMR data. These compounds were tested for their activity to inhibit aromatase. It was observed that the introduction of an imidazolyl group at carbon 4 on flavan nucleus led to very potent molecules.

Neuroprotection Against Ischemic Brain Injury Conferred by a Novel Nitrate Ester


Bioorg. Med. Chem. Lett. 12 (2002) 2863

James N. Reynolds,^b Brian M. Bennett,^b Roland J. Boegman,^b Khem Jhamandas,^b Jodan D. Ratz,^b Sergei I. Zavorin,^a Dan Scutaru,^a Adina Dumitrascu^a and Gregory R. J. Thatcher^{a,b,*}

^aDepartment of Chemistry, Queen's University, Kingston, ON, Canada K7L 3N6

^bDepartment of Pharmacology and Toxicology, Queen's University, Kingston, ON, Canada K7L 3N6

A novel nitrate is neuroprotective in the MCAO in vivo stroke model when administered post-ischemia.



Benzodiazepine Inhibitors of the MMPs and TACE


Bioorg. Med. Chem. Lett. 12 (2002) 2867

Frances C. Nelson,^{a,*} Efren Delos Santos,^a Jeremy I. Levin,^a James M. Chen,^a Jerauld S. Skotnicki,^a John F. DiJoseph,^b Michele A. Sharr,^b Amy Sung,^b Loran M. Killar,^b Rebecca Cowling,^a Guixian Jin,^a Catherine E. Roth^b and J. Donald Albright^a

^aWyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA

^bWyeth Research, PO Box CN8000, Princeton, NJ 08543, USA

A series of benzodiazepine inhibitors of the MMPs and TACE has been developed. These compounds display an interesting selectivity profile and should be useful tools for exploring the biological relevance of such selectivity.




Synthesis and Muscarinic M₂ Subtype Antagonistic Activity of Unnatural *ent*-Himbacine and an Enantiomeric Pair of (2'*S*,6'*R*)-Diepihimbacine

Bioorg. Med. Chem. Lett. 12 (2002) 2871

Masanori Takadoi^{a,*} and Shiro Terashima^b

^aDiscovery Research Laboratories, Kyorin Pharmaceutical Company Ltd., 2399-1 Nogi, Nogi-machi, Tochigi 329-0114, Japan

^bSagami Chemical Research Center, 2743-1 Hayakawa, Ayase, Kanagawa 252-1193, Japan



Solid-Phase Synthesis and Investigation of Benzofurans as Selective Estrogen Receptor Modulators

Bioorg. Med. Chem. Lett. 12 (2002) 2875


Roger A. Smith,^{a,*} Jinshan Chen,^a Mary M. Mader,^a Ingo Muegge,^a Ulrike Moehler,^a Suresh Katti,^b Diana Marrero,^b William G. Stirtan,^b Daniel R. Weaver,^c Hong Xiao^c and William Carley^c

^aDepartment of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA

^bDepartment of Research Technologies, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA

^cDepartment of Cancer and Osteoporosis Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA

A library of benzofurans was prepared by solid-phase synthesis methods, and several analogues were identified as potent ligands for the estrogen receptors ER- α and ER- β , with some compounds having selectivity for ER- α . Analogues designed to more closely mimic Raloxifene were less effective. Certain benzofurans were effective in a bone pit assay, but were characterized as agonists in a MCF-7 breast tumor cell proliferation assay.




Novel Amide-Based Inhibitors of Inosine 5'-Monophosphate Dehydrogenase

Bioorg. Med. Chem. Lett. 12 (2002) 2879

Scott H. Watterson,^{*} Chunjian Liu, T. G. Murali Dhar, Henry H. Gu, William J. Pitts, Joel C. Barrish, Catherine A. Fleener, Katherine Rouleau, N. Z. Sherbina, Diane L. Hollenbaugh and Edwin J. Iwanowicz

Bristol-Myers Squibb PRI, PO Box 4000, Princeton, NJ 08543-4000, USA

The preparation and in vitro biological evaluation of a series of novel amide-based small molecule inhibitors of inosine monophosphate dehydrogenase are described.



Albumin Affinity Tags Increase Peptide Half-Life In Vivo

Bioorg. Med. Chem. Lett. 12 (2002) 2883


Michael F. T. Koehler,^{a,*} Kerry Zobel,^a Maureen H. Beresini,^b Lisa D. Caris,^b Daniel Combs,^c Brian D. Paasch^b and Robert A. Lazarus^a

^aDepartment of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

^bDepartment of BioAnalytical Research and Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

^cDepartment of Clinical and Experimental Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA


Small molecule tags with high affinity for serum albumin reduce clearance and increase the circulating half-life of bioactive peptides administered to rabbits.



Novel Route to the Synthesis of Peptides Containing 2-Amino-1'-hydroxymethyl Ketones and Their Application as Cathepsin K Inhibitors

Rohan V. Mendonca,* Shankar Venkatraman and James T. Palmer
Celera, 180 Kimball Way, South San Francisco, CA 94080, USA

A new synthetic route to hydroxymethyl and alkoxymethyl ketones is reported.




Bioorg. Med. Chem. Lett. 12 (2002) 2887

Syntheses and EGFR and HER-2 Kinase Inhibitory Activities of 4-Anilinoquinoline-3-carbonitriles: Analogues of Three Important 4-Anilinoquinazolines Currently Undergoing Clinical Evaluation as Therapeutic Antitumor Agents

Allan Wissner,* M. Brawner Floyd, Sridhar K. Rabindran,
Ramaswamy Nilakantan, Lee M. Greenberger, Ru Shen,
Yu-Fen Wang and Hwei-Ru Tsou

Chemical Sciences and Oncology and Immunoinflammatory Research, Wyeth Research,
401 N. Middletown Road, Pearl River, NY 10965, USA




Bioorg. Med. Chem. Lett. 12 (2002) 2893

Molecular Modeling and Enzymatic Studies of the Interaction of a Choline Analogue and Acetylcholinesterase

Stefano Alcaro,^{a,*} Luigi Scipione,^b Francesco Ortuso,^a Salvatore Posca,^b Vincenzo Rispoli^a
and Domenicantonio Rotiroti^a

^aDipartimento di Scienze Farmacobiologiche, Università degli Studi 'Magna Græcia' di Catanzaro,
Complesso 'Nini Barbieri', I-88021 Roccelletta di Borgia (CZ), Italy

^bDipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive,
Università degli Studi 'La Sapienza' di Roma, P. le A. Moro, 5, 00185 Rome, Italy



Pivaloyl-choline iodide **1** interactions with acetylcholinesterase (AChE) have been studied by theoretical and enzymatic methods. An integrated computational approach has clearly shown a substrate rather than inhibitory profile for **1**. Enzymatic experiments have also supported the same theoretical conclusion indicating that AChE was able to hydrolyze **1** to choline.


Bioorg. Med. Chem. Lett. 12 (2002) 2899

Targeting Thrombin and Factor VIIa: Design, Synthesis, and Inhibitory Activity of Functionally Relevant Indolizidinones

Stephen Hanessian,^{a,*} Eric Therrien,^a Kenneth Granberg^b and Ingemar Nilsson^b

^aDepartment of Chemistry, Université de Montréal, PO Box 6128,
Station Centre-ville, Montréal, QC, Canada H3C 3J7

^bAstraZeneca R&D Mölndal, Medicinal Chemistry, Mölndal, Sweden



3, R¹ = , R² = NH₂

4, R¹ = , R² = NH₂

5, R¹ = , R² = NH₂

6, R¹ = NH₂, R² =

Bioorg. Med. Chem. Lett. 12 (2002) 2907

Solid-Phase Synthesis of Dual $\alpha_4\beta_1/\alpha_4\beta_7$ Integrin Antagonists: Two Scaffolds with Overlapping Pharmacophores


Bioorg. Med. Chem. Lett. 12 (2002) 2913

Georgette M. Castanedo,^a Fredrick C. Sailes,^a Nathan J. P. Dubree,^a John B. Nicholas,^a Lisa Caris,^b Kevin Clark,^b Susan M. Keating,^b Maureen H. Beresini,^b Henry Chiu,^c Sherman Fong,^c James C. Marsters, Jr.,^a David Y. Jackson^a and Daniel P. Sutherlin^{a,*}

^aDepartment of Bioorganic Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA

^bDepartment of Pharmacology, Genentech, Inc., South San Francisco, CA 94080, USA

^cDepartment of Immunology, Genentech, Inc., South San Francisco, CA 94080, USA




Succinimide Hydroxamic Acids as Potent Inhibitors of Histone Deacetylase (HDAC)

Bioorg. Med. Chem. Lett. 12 (2002) 2919

Michael L. Curtin,^{*} Robert B. Garland, H. Robin Heyman, Robin R. Frey, Michael R. Michaelides, Junling Li, Lori J. Pease, Keith B. Glaser, Patrick A. Marcotte and Steven K. Davidsen

Cancer Research Area, Abbott Laboratories, Dept. 47J, Bldg. AP10, 100 Abbott Park Road, Abbott Park, IL 60064, USA

The evaluation of HDAC inhibitor **6** (IC₅₀ 38 nM) and simplified succinimide hydroxamic acid analogues is reported.




Non-covalent Thrombin Inhibitors Featuring P₃-heterocycles with P₁-Bicyclic Arginine Surrogates[†]

Bioorg. Med. Chem. Lett. 12 (2002) 2925

Jingrong Jean Cui, Gian-Luca Araldi, John E. Reiner, Komandla Malla Reddy, Scott J. Kemp, Jonathan Z. Ho, Daniel V. Siev, Lala Mamedova, Tony S. Gibson, John A. Gaudette, Nathaniel K. Minami, Susanne M. Anderson, Annette E. Bradbury, Thomas G. Nolan and J. Edward Semple^{*}

Department of Medicinal Chemistry, Corvas International, Inc., 3030 Science Park Road, San Diego, CA 92121, USA

The design, synthesis and biological activity of achiral, non-covalent, orally bioavailable thrombin inhibitors **NC1–NC44** is disclosed that feature weakly basic bicyclic P₁-arginine mimics including indazoles, benzimidazoles, indoles, benzotriazoles and aminobenzisoxazoles.




Novel Guanidine-Based Inhibitors of Inosine Monophosphate Dehydrogenase

Bioorg. Med. Chem. Lett. 12 (2002) 2931

Edwin J. Iwanowicz,^{*} Scott H. Watterson, Chunjian Liu, Henry H. Gu, Toomas Mitt, Katerina Leftheris, Joel C. Barrish, Catherine A. Fleener, Katherine Rouleau, N. Z. Sherbina and Diane L. Hollenbaugh

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA

A series of novel guanidine-based inhibitors of IMPDH II was prepared and the structure–activity relationships (SARs) are described. Studies were focused on replacing a urea moiety, key to potent biological activity for a previously described chemical series. Compound **6l** was identified as a potent inhibitor of IMPDH II with an IC₅₀(16 nM) comparable to mycophenolic acid.



Structure–Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A_{2A} Receptor

Bioorg. Med. Chem. Lett. 12 (2002) 2935


Venkata P. Palle,^{a,*} Elfatih O. Elzein,^{a,*} Scott A. Gothe,^c Zhihe Li,^b Zhenhai Gao,^b Stephanie Meyer,^b Brent Blackburn^{a,b} and Jeff A. Zablocki^a

^aDepartment of Bioorganic Chemistry, CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA

^bDepartment of Pharmacological Sciences, CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA

^cTripos, Inc., 601 Gateway Blvd. Suite 720, So. San Francisco, CA, USA

The SAR of two series of A_{2A} adenosine agonists are reported.




Nodulisporic Acid B, B₁, and B₂: A Series of 1'-Deoxy-nodulisporic Acids from *Nodulisporium* sp.

Bioorg. Med. Chem. Lett. 12 (2002) 2941

John G. Ondeyka,* Arlene M. Dahl-Roshak, Jan S. Tkacz, Deborah L. Zink, Michelle Zakson-Aiken, Wesley L. Shoop, Michael A. Goetz and Sheo B. Singh

Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA

Discovery and biological activities of a series of 1'-deoxy-nodulisporic acid congeners nodulisporic acids B, B₁ and B₂ have been described.




Successful Bridging from a Peptide to a Non Peptide Antagonist at the Human Tachykinin NK-2 Receptor

Bioorg. Med. Chem. Lett. 12 (2002) 2945

Maria Altamura, Franca Canfarini, Rose-Marie Catalioto, Antonio Guidi,* Franco Pasqui, Anna R. Renzetti, Antonio Triolo and Carlo A. Maggi

Menarini Ricerche S.p.A., Via dei Sette Santi 3, 50131 Florence, Italy

Novel non peptide antagonists at the hNK-2 receptor have been derived from a potent peptide antagonist.



Cytotoxic Activity of Aminoderivatized Cationic Chitosan Derivatives

Bioorg. Med. Chem. Lett. 12 (2002) 2949


Jung-Kul Lee,^a Hyun-Soo Lim^b and Jung-Hoe Kim^{c,*}

^aBioNgene Co., Ltd., 10-1, 1Ka Myungryun-Dong, Chongro-Ku, Seoul, 110-521, South Korea

^bDivision of Biotechnology and Chemical Engineering, Yosu National University, San 96-1 Dunduck-dong, Yeosu Jeollanam-Do, 550-749, South Korea

^cDepartment of Biological Sciences, Korea Advanced Institute of Science and Technology, 307-1 Kusong-Dong, Yusong-Ku, Taejon-Si, 449-791, South Korea

Chitosan derivatives were prepared by dialkylaminoalkylation and reductive amination followed by quaternization. Cytotoxic activity of the chitosan derivatives was investigated and a relationship between structure and activity is suggested.




Cytotoxic Acridinylthiourea and Its Platinum Conjugate Produce Enzyme-Mediated DNA Strand Breaks

Bioorg. Med. Chem. Lett. 12 (2002) 2953

Jennifer M. Brow, Cynthia R. Pleatman and Ulrich Bierbach*

Department of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA

The novel acridinylthiourea, 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea (**1**), has been identified as a dual topoisomerase I/II poison. As a carrier ligand in the DNA-directed platinum-acridine conjugate, **2**, acridine turns the metallodrug into a topoisomerase II poison.



Novel Substituted 4-Aminomethylpiperidines as Potent and Selective Human β_3 -Agonists. Part 1: Aryloxypropanolaminomethylpiperidines

Bioorg. Med. Chem. Lett. 12 (2002) 2957

Robert J. Steffan,^{a,*} Mark A. Ashwell,^a William R. Solvibile,^a Edward Matelan,^a Elwood Largis,^b Stella Han,^b Jeffery Tillet^b and Ruth Mulvey^b

^aChemical Sciences, Wyeth Research, 500 Arcola Rd, Collegeville, PA 19426, USA

^bCardiovascular/Metabolic Diseases, Wyeth Research, 500 Arcola Rd, Collegeville, PA 19426, USA

The synthesis and SAR of a series of human β_3 adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified that were in vitro active in CHO cells expressing human β_3 -AR (EC_{50} = 49 nM, IA = 1.1), and in vivo active in a transgenic mouse model.

Novel Substituted 4-Aminomethylpiperidines as Potent and Selective Human β_3 -Agonists. Part 2: Arylethanolaminomethylpiperidines

Bioorg. Med. Chem. Lett. 12 (2002) 2963

Robert J. Steffan,^{a,*} Mark A. Ashwell,^a William R. Solvibile,^a Edward Matelan,^a Elwood Largis,^b Stella Han,^b Jeffery Tillet^b and Ruth Mulvey^b

^aChemical Sciences, Wyeth Research, 500 Arcola Rd, Collegeville, PA 19426, USA

^bCardiovascular/Metabolic Diseases, Wyeth Research, 500 Arcola Rd, Collegeville, PA 19426, USA

The synthesis and SAR of a series of β_3 adrenoreceptor agonists based on a novel template derived from 4-aminomethylpiperidine coupled with a common pharmacophore, arylethylamine, is described. This combination led to the identification of human β_3 adrenoreceptor agonists with in vivo activity in a transgenic mouse model.


Acyl Dipeptides as Reversible Caspase Inhibitors. Part 1: Initial Lead Optimization

Bioorg. Med. Chem. Lett. 12 (2002) 2969

Steven D. Linton,^{*} Donald S. Karanewsky, Robert J. Ternansky, Joe C. Wu, Brian Pham, Lalitha Kodandapani, Robert Smidt, Jose-Luis Diaz, Lawrence C. Fritz and Kevin J. Tomaselli

Idun Pharmaceuticals, Inc., 9380 Judicial Drive, San Diego, CA 92121, USA

Parallel synthesis was used to explore the SAR of a peptidomimetic caspase inhibitor. The most potent compound had nanomolar activity against caspases 1, 3, 6, 7, and 8.



Acyl Dipeptides as Reversible Caspase Inhibitors.

Bioorg. Med. Chem. Lett. 12 (2002) 2973


Part 2: Further Optimization

Steven D. Linton,^{a,*} Donald S. Karanewsky,^a Robert J. Ternansky,^a Ning Chen,^a Xian Guo,^a Kathy G. Jahangiri,^a Vincent J. Kalish,^a Steven P. Meduna,^a Edward D. Robinson,^a Brett R. Ullman,^a Joe C. Wu,^a Brian Pham,^a Lalitha Kodandapani,^a Robert Smidt,^a Jose-Luis Diaz,^a Lawrence C. Fritz,^a U. von Krosigk,^b Silvio Roggo,^b Albert Schmitz^b and Kevin J. Tomaselli^a

^aIdun Pharmaceuticals, Inc., 9380 Judicial Drive, San Diego, CA 92121, USA

^bNovartis Pharma Ltd., Pharma Research, CH-4002 Basel, Switzerland

A new structural class of broad spectrum caspase inhibitors was optimized for its activity against caspases 1, 3, 6, 7, and 8. The most potent compound had low nanomolar broad spectrum activity, in particular, single digit nanomolar inhibitory activity against caspase 8.




Synthesis and Evaluation of 7-Substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide Derivatives as K_{ATP} Channel Agonists

Bioorg. Med. Chem. Lett. 12 (2002) 2977

Andrew J. Peat,^{*} Claire Townsend, Jennings F. Worley III, Scott H. Allen, Dulce Garrido, Robert J. Mertz, Jeffrey L. Pfohl, Christopher M. Terry, Jim F. Truax, Robert L. Veasey and Stephen A. Thomson

GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA

A series of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives has been synthesized and evaluated as K_{ATP} channel agonists using the inside-out excised patch clamp technique. The most active compounds were ~20-fold more potent than diazoxide in opening K_{ATP} channels. A linear relationship exists between the potency of the compound and the sigma value of the 7-substituent with electron-withdrawing groups exhibiting higher activity. These compounds may be useful in modulating insulin release from pancreatic β -cells and in diseases associated with hyperinsulinemia.



Novel Benzthiodiazepinones as Antiherpetic Agents: SAR Improvement of Therapeutic Index by Alterations of the Seven-Membered Ring


Bioorg. Med. Chem. Lett. 12 (2002) 2981

Harriet W. Hamilton,^{a,*} Gisele Nishiguchi,^a Susan E. Hagen,^a John D. Domagala,^a Peter C. Weber,^a Stephen Gracheck,^a Stefanie L. Boulware,^a Eric C. Nordby,^a Hidetsura Cho,^b Takeshi Nakamura,^b Satoru Ikeda^b and Wataru Watanabe^b

^aDepartments of Chemistry and Infectious Diseases, Pfizer Global R&D, Ann Arbor, MI 48118, USA

^bDepartments of Chemical and Biological Research, Japan Tobacco Inc., Central Pharmaceutical Research Institute, Takatsuki, Osaka, Japan

A series of novel benzthiodiazepinones was studied as antiherpetic agents. Significant improvements in potency and therapeutic index in a viral replication assay were realized over the starting molecule.




Protein Degradation with Photoactivated Enediyne-Amino Acid Conjugates

Bioorg. Med. Chem. Lett. 12 (2002) 2985

Gary Plourde, II, Ahmed El-Shafey, Farid S. Fouad, Ajay S. Purohit and Graham B. Jones^{*}

Department of Chemistry, Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA

A series of photoactivated enediynes was prepared, and successfully employed for the selective degradation of target proteins.



Substituted 4-Anilino-7-phenyl-3-quinolinecarbonitriles as Src Kinase Inhibitors


Bioorg. Med. Chem. Lett. 12 (2002) 2989

Dan Berger,^{a,*} Minu Dutia,^a Dennis Powell,^a Allan Wissner,^a Frenel DeMorin,^a Yuri Raifeld,^a Jennifer Weber^b and Frank Boschelli^b

^aChemical Sciences, Wyeth Research, Pearl River, NY 10965, USA

^bDiscovery Oncology, Wyeth Research, Pearl River, NY 10965, USA

A series of 4-anilino-7-phenyl-3-quinolinecarbonitriles with water-solubilizing groups attached via the C-7 phenyl ring was prepared as Src kinase inhibitors.




General Solid-Phase Method to Prepare Novel Cyclic Ketone Inhibitors of the Cysteine Protease Cruzain

Bioorg. Med. Chem. Lett. 12 (2002) 2993

Lily Huang and Jonathan A. Ellman

Center for New Directions in Organic Synthesis, Department of Chemistry, University of California, Berkeley, CA 94720, USA

A series of constrained ketone-based inhibitors has been developed that show low nanomolar K_i values. These ketone inhibitors showed promising activity towards cruzain, the cysteine protease implicated in Chagas' disease. This series of constrained inhibitors, which can be accessed quickly and efficiently using a solid-phase combinatorial strategy, should be applicable to other members of the cysteine protease class.



1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 3: Polar Functionality and Its Effect on Anti-HIV-1 Activity

Bioorg. Med. Chem. Lett. 12 (2002) 2997


Jeffrey J. Hale,^{a,*} Richard J. Budhu,^a Sander G. Mills,^a Malcolm MacCoss,^a Sandra L. Gould,^b Julie A. DeMartino,^b Martin S. Springer,^b Salvatore J. Siciliano,^b Lorraine Malkowitz,^b William A. Schleif,^c Daria Hazuda,^c Michael Miller,^c Joseph Kessler,^c Renee Danzeisen,^c Karen Holmes,^c Janet Lineberger,^c Anthony Carella,^c Gwen Carver^c and Emilio A. Emini^c

^aDepartment of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA

^bDepartment of Immunology Research, Merck Research Laboratories, Rahway, NJ 07065, USA

^cDepartment of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA

Incorporation of acidic functional groups into a lead CCR5 antagonist **2** identified from a targeted combinatorial library resulted in compounds exemplified by **16** with enhanced anti-HIV-1 activity and attenuated L-type calcium channel affinity.



1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 4: Synthesis of N-1 Acidic Functionality Affording Analogues with Enhanced Antiviral Activity Against HIV

Bioorg. Med. Chem. Lett. 12 (2002) 3001

Christopher L. Lynch,^{a,*} Jeffrey J. Hale,^a Richard J. Budhu,^a Amy L. Gentry,^a Sander G. Mills,^a Kevin T. Chapman,^a Malcolm MacCoss,^a Lorraine Malkowitz,^b Martin S. Springer,^b Sandra L. Gould,^b Julie A. DeMartino,^b Salvatore J. Siciliano,^b Margaret A. Cascieri,^b Anthony Carella,^c Gwen Carver,^c Karen Holmes,^c William A. Schleif,^c Renee Danzeisen,^c Daria Hazuda,^c Joseph Kessler,^c Janet Lineberger,^c Michael Miller^c and Emilio A. Emini^c

^aDepartment of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA

^bDepartment of Immunology Research, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA

^cDepartment of Antiviral Research, Merck Research Laboratories, PO Box 4, West Point, PA 19486, USA

(–)6-*n*-Propylnicotine Antagonizes the Antinociceptive Effects of (–)Nicotine


Bioorg. Med. Chem. Lett. 12 (2002) 3005

Małgorzata Dukat,^a Mohamed El-Zahabi,^a Giovanni Ferretti,^a M. Imad Damaj,^b Billy R. Martin,^b Richard Young^a and Richard A. Glennon^{a,b,*}

^a*Department of Medicinal Chemistry, School of Pharmacy, Box 980540, Virginia Commonwealth University, Richmond, VA 23298-0540, USA*

^b*Department of Pharmacology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298-0540, USA*

(–)6-Ethyl nicotine is a nACh receptor agonist. However, its 6-*n*-propyl homologue (–)**4** binds at nACh receptors with similar affinity yet antagonizes the antinociceptive effects, but not the locomotor or stimulus effects, of (–)nicotine.



Substituted 4-(2,2-Diphenylethyl)pyridine-*N*-oxides as Phosphodiesterase-4 Inhibitors: SAR Study Directed Toward the Improvement of Pharmacokinetic Parameters

Bioorg. Med. Chem. Lett. 12 (2002) 3009

Richard Frenette,* Marc Blouin, Christine Brideau, Nathalie Chauret, Yves Ducharme, Richard W. Friesen, Pierre Hamel, Tom R. Jones, France Laliberté, Chun Li, Paul Masson, Malia McAuliffe and Yves Girard
Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe-Claire-Dorval, Québec, Canada H9R 4P8

A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The introduction of a soft metabolic site on this structure permitted the identification of L-826,141 as a potent phosphodiesterase type 4 (PDE4) inhibitor showing a shorter half-life than L-791,943 in a variety of animal species and also in vivo efficacy in different models.